Clinical Trials Browser

Terminated × Small Cell Lung Carcinoma × Nivolumab × Clear all

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Phase 1 Terminated

249 enrolled 43 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT03662074 2023-08-02

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 14 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03406715 2023-03-30

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Phase 2 Terminated

14 enrolled 12 charts

Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04173325 2022-06-14

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Phase 1 Terminated

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Terminated

42 enrolled 15 charts

Neoplasms, Small Cell Lung Carcinoma